Pfizer Showcases Oncology Pipeline Advances at ESMO 2026

  • Pfizer will present data from 45 abstracts at ESMO 2026, including 11 oral presentations across breast, genitourinary, and lung cancers.
  • Phase 2 results for atirmociclib in advanced breast cancer support its potential as a first-in-class treatment.
  • Late-breaking overall survival data for sigvotatug vedotin in non-small cell lung cancer will be unveiled.
  • Updated Phase 2 data for tivunatamig in combination with chemotherapy in first-line NSCLC will be presented.

Pfizer's extensive data presentation at ESMO 2026 underscores its strategic focus on advancing both current standards of care and next-generation oncology treatments. The company's emphasis on breast, genitourinary, and lung cancers aligns with its goal to impact patients globally. The ongoing Phase 3 studies and planned trials highlight Pfizer's commitment to expanding its oncology portfolio through innovative therapies and strategic collaborations.

Pipeline Progress
Whether Pfizer's investigational candidates like atirmociclib and tivunatamig can secure regulatory approvals and become blockbuster therapies.
Combination Therapies
The pace at which Pfizer advances combination therapies, particularly with PADCEV and pembrolizumab, in various cancer indications.
Regulatory Approvals
The timeline for FDA's review of the sNDA for TALZENNA plus XTANDI in metastatic castration-sensitive prostate cancer.